CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids, doa doa di mina
Casa
doa doa di mina

CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids

Por um escritor misterioso

Descrição
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
CRISPR-AsCas12a Efficiently Corrects a GPR143 Intronic Mutation in
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
Enhanced genome editing in human iPSCs with CRISPR-CAS9 by co
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
Characterisation of a novel OPA1 splice variant resulting in
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
IJMS, Free Full-Text
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
Metabolic rescue ameliorates mitochondrial encephalo
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
Functional genomics and the future of iPSCs in disease modeling
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
PDF) Modelling autosomal dominant optic atrophy associated with
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
Retinal Ganglion Cells in a Dish: Current Strategies and
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
OPA1 Mutation and Late‐Onset Cardiomyopathy: Mitochondrial
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
Retinal Ganglion Cells in a Dish: Current Strategies and
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
OPA1 regulation of mitochondrial dynamics in skeletal and cardiac
CRISPR-Cas9 correction of OPA1 c.1334G>A: p.R445H restores mitochondrial homeostasis in dominant optic atrophy patient-derived iPSCs: Molecular Therapy - Nucleic Acids
OPA1 Mutation and Late‐Onset Cardiomyopathy: Mitochondrial
de por adulto (o preço varia de acordo com o tamanho do grupo)